Biotech | May 02, 2022
NORD announces over US $ 100,000 in grant funding available for rare disease research
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Subscribe To Our Newsletter & Stay Updated
